According to a Financial Times report Friday citing people familiar with the matter, AstraZeneca is working with bankers on the potential sale of rights to future revenue streams from certain existing drugs. The report suggested the move could make AstraZeneca less appealing to recent suitor Pfizer by eliminating access to some future income in the event of a takeover, while also generating billions in revenue that could be returned to shareholders or used to fund R&D.
Help employers find you! Check out all the jobs and post your resume.
